Design Therapeutics, Inc. (DSGN) — SEC Filings
Design Therapeutics, Inc. (DSGN) — 21 SEC filings. Latest: 10-Q (Apr 28, 2026). Includes 7 10-Q, 5 8-K, 3 SC 13G/A.
View Design Therapeutics, Inc. on SEC EDGAR
Overview
Design Therapeutics, Inc. (DSGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Apr 28, 2026: Design Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2026. The filing includes financial statements and other disclosures relevant to investors. The company is located at 6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011.
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 2 bearish, 19 neutral. The dominant filing sentiment for Design Therapeutics, Inc. is neutral.
Filing Type Overview
Design Therapeutics, Inc. (DSGN) has filed 1 4, 7 10-Q, 5 8-K, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of DSGN's 17 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$53.795M |
| EPS | -$0.30 |
| Debt-to-Equity | N/A |
| Cash Position | $206.0M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- David Shapiro
- Derek Gould
- Pratik Shah
Industry Context
Design Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on gene therapy for rare genetic diseases. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovative technology platforms like GeneTAC and the ability to navigate clinical trials and secure regulatory approvals.
Top Tags
10-Q (5) · financials (4) · quarterly-report (2) · ownership-change (2) · Biotechnology (2) · Net Loss (2) · R&D Expenses (2) · Cash Burn (2) · governance (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period End Date | 2026-03-31 | Indicates the financial reporting period covered by the 10-Q. |
| Filing Date | 2026-04-28 | The date the 10-Q was officially submitted to the SEC. |
| Net Loss (9 months ended Sep 30, 2025) | $53.795M | Increased from $35.937M in 2024, a 49.69% increase |
| Accumulated Deficit (as of Sep 30, 2025) | $281.0M | Increased from $227.214M at Dec 31, 2024 |
| Total Operating Expenses (9 months ended Sep 30, 2025) | $61.298M | Increased from $45.689M in 2024 |
| Research and Development Expenses (9 months ended Sep 30, 2025) | $45.704M | Increased from $32.193M in 2024 |
| Cash, Cash Equivalents and Investment Securities (as of Sep 30, 2025) | $206.0M | Decreased from $245.477M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (9 months ended Sep 30, 2025) | $42.392M | Increased from $33.245M in 2024 |
| Net Loss (3 months ended Sep 30, 2025) | $16.997M | Increased from $13.039M in 2024 |
| Shares Outstanding (as of Oct 31, 2025) | 56,963,757 | Slight increase from 56,754,341 at Dec 31, 2024 |
| Interest Income (9 months ended Sep 30, 2025) | $7.503M | Decreased from $9.752M in 2024 |
| Net Loss Per Share (3 months ended Sep 30, 2025) | $0.30 | Increased from $0.23 in 2024 |
| Net Loss for Q2 2025 | $26.8 million | Increased by 10.3% from $24.3 million in Q2 2024 |
| Net Loss for H1 2025 | $53.3 million | Increased by 10.8% from $48.1 million in H1 2024 |
| Revenue | $0 | No revenue reported for Q2 or H1 2025, consistent with pre-commercial stage |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Design Therapeutics, Inc. (DSGN)?
Design Therapeutics, Inc. has 21 recent SEC filings from Jan 2024 to Apr 2026, including 7 10-Q, 5 8-K, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DSGN filings?
Across 21 filings, the sentiment breakdown is: 2 bearish, 19 neutral. The dominant sentiment is neutral.
Where can I find Design Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Design Therapeutics, Inc. (DSGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Design Therapeutics, Inc.?
Key financial highlights from Design Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DSGN?
The investment thesis for DSGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Design Therapeutics, Inc.?
Key executives identified across Design Therapeutics, Inc.'s filings include David Shapiro, Derek Gould, Pratik Shah.
What are the main risk factors for Design Therapeutics, Inc. stock?
Of DSGN's 17 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Design Therapeutics, Inc.?
Forward guidance and predictions for Design Therapeutics, Inc. are extracted from SEC filings as they are enriched.